DongKoo Bio & Pharma Co., Ltd. (KOSDAQ: 006620)

DongKoo Bio & Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2017
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2017
Operating Revenue	252,716	215,064	194,496	155,131	139,216	101,124
Other Revenue	994.64	622	491.86	17.86	-	-
Revenue	253,710	215,686	194,988	155,149	139,216	101,124
Revenue Growth (YoY)	25.78%	10.62%	25.68%	11.45%	37.67%	15.75%
Cost of Revenue	98,510	83,610	77,128	62,812	58,673	40,334
Gross Profit	155,200	132,076	117,860	92,337	80,543	60,791
Selling, General & Admin	126,278	105,674	91,394	72,852	60,016	42,906
Research & Development	9,641	10,752	8,258	10,114	10,751	3,681
Other Operating Expenses	349.93	204.13	273.54	282.42	249.5	162.65
Operating Expenses	137,064	117,460	101,023	84,198	72,932	47,450
Operating Income	18,137	14,616	16,836	8,139	7,611	13,340
Interest Expense	-2,502	-1,760	-1,039	-415.63	-430.83	-574.32
Interest & Investment Income	294.76	310.5	179.43	50.88	77.57	32.88
Earnings From Equity Investments	-3,316	-	-	-	-	-528.35
Currency Exchange Gain (Loss)	-43.05	20.79	30.37	101.41	-61.72	345.17
Other Non Operating Income (Expenses)	119.65	287.04	956.37	4,102	473.76	472.23
EBT Excluding Unusual Items	12,690	13,474	16,963	11,978	7,670	13,088
Gain (Loss) on Sale of Investments	3,710	2,881	4,501	1,827	7,453	3.15
Gain (Loss) on Sale of Assets	4,671	401.74	136.72	2,258	-57.93	65.35
Asset Writedown	-1,385	-2,016	-13,685	-4,728	-4,765	-
Pretax Income	19,686	14,741	7,916	11,333	10,300	13,156
Income Tax Expense	4,382	2,932	1,302	2,007	1,160	2,213
Earnings From Continuing Operations	15,304	11,808	6,614	9,327	9,140	10,943
Minority Interest in Earnings	32.31	3.17	-	-	-	-
Net Income	15,337	11,812	6,614	9,327	9,140	10,943
Net Income to Common	15,337	11,812	6,614	9,327	9,140	10,943
Net Income Growth	124.79%	78.59%	-29.09%	2.04%	-16.47%	0.28%
Shares Outstanding (Basic)	27	28	28	28	28	22
Shares Outstanding (Diluted)	27	28	28	28	28	22
Shares Change (YoY)	-0.73%	-0.48%	-1.78%	-0.12%	25.96%	-20.35%
EPS (Basic)	558.81	427.63	238.29	330.05	323.08	493.91
EPS (Diluted)	558.81	427.63	238.29	330.05	323.08	475.00
EPS Growth	126.45%	79.46%	-27.80%	2.16%	-31.98%	22.74%
Free Cash Flow	-7,156	-10,260	11,841	13,637	2,221	8,696
Free Cash Flow Per Share	-260.75	-371.44	426.63	482.57	78.50	387.18
Dividend Per Share	120.000	120.000	-	-	-	-
Gross Margin	61.17%	61.24%	60.44%	59.51%	57.85%	60.11%
Operating Margin	7.15%	6.78%	8.63%	5.25%	5.47%	13.19%
Profit Margin	6.04%	5.48%	3.39%	6.01%	6.57%	10.82%
Free Cash Flow Margin	-2.82%	-4.76%	6.07%	8.79%	1.60%	8.60%
EBITDA	24,820	20,644	22,469	13,193	12,117	15,547
EBITDA Margin	9.78%	9.57%	11.52%	8.50%	8.70%	15.37%
D&A For EBITDA	6,684	6,028	5,632	5,054	4,506	2,207
EBIT	18,137	14,616	16,836	8,139	7,611	13,340
EBIT Margin	7.15%	6.78%	8.63%	5.25%	5.47%	13.19%
Effective Tax Rate	22.26%	19.89%	16.44%	17.71%	11.26%	16.82%
Advertising Expenses	-	1,595	1,630	1,971	3,013	1,412

Source: S&P Capital IQ. Standard template. Financial Sources.